Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 6;20(4):414-424.
doi: 10.1093/ntr/ntx097.

Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

Affiliations
Free PMC article
Review

Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How

Li-Shiun Chen et al. Nicotine Tob Res. .
Free PMC article

Abstract

This article outlines a framework for the consistent integration of biological data/samples into smoking cessation pharmacotherapy trials, aligned with the objectives of the recently unveiled Precision Medicine Initiative. Our goal is to encourage and provide support for treatment researchers to consider biosample collection and genotyping their existing samples as well as integrating genetic analyses into their study design in order to realize precision medicine in treatment of nicotine dependence.

Figures

Figure 1.
Figure 1.
Biological systems multi-omics from the genome, epigenome, transcriptome, proteome and metabolome to the phenome. SNP, single-nucleotide polymorphism; CNV, copy number variation; miRNA, micro RNA.
Figure 2.
Figure 2.
Example: Benefits of nicotine replacement therapy may vary by genetic marker. Blue: patients who benefit; Clear: patients who fail to benefit,, both studies of European Ancestry.
Figure 3.
Figure 3.
Pharmacogenomic trial designs, including retrospective, prospective stratified, and prospective screened. Source: Adapted from Lerman, IOM workshop presentation on November 17, 2010.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles
Feedback